News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eagle Pharmaceuticals (EGRX) Reports Third Quarter 2014 Results


8/11/2014 8:36:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three-month period ended June 30, 2014. Highlights of the third quarter of 2014 and subsequent events include:



* The U.S. Food and Drug Administration (“FDA”) approved Ryanodex® (dantrolene sodium) injectable suspension indicated for the treatment of malignant hyperthermia (“MH”), along with the appropriate supportive measures. Shipments are expected to start near the end of August.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES